A randomized phase III study of i.v. [intravenous] zoledronate [zoledronic acid] (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma, A phase III study.
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Multiple myeloma
- Focus Therapeutic Use
- 16 May 2009 Trial location (Netherlands) identified as reported by as reported by ISRCTN: Current Controlled Trials.
- 10 Feb 2006 New trial record.